Filing Flows › Journey Medical (DERM) › Qbrexza revenue
Journey Medical (DERM) Qbrexza revenue by quarter
Journey Medical's Qbrexza revenue was $5.1M in Q2 2026 (second quarter 2026), +2% from Q1 2026. Over the last 7 quarters it ranged from $5.0M (Q1 2026) to $7.4M (Q3 2025).
| Quarter | Qbrexza revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $5.1M | +2% | -26% |
| Q1 2026 | $5.0M | -9% | -3% |
| Q4 2025 | $5.5M | -25% | -2% |
| Q3 2025 | $7.4M | +6% | — |
| Q2 2025 | $6.9M | +35% | — |
| Q1 2025 | $5.2M | -9% | — |
| Q4 2024 | $5.7M | — | — |
Q2 2026 at a glance
Journey Medical, Q2 2026: revenue $18.5M (+23% year over year), operating margin 2.5%, net loss $312K, operating cash flow −$1.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Journey Medical's Qbrexza revenue?
Journey Medical's Qbrexza revenue was $5.1M in Q2 2026 (second quarter 2026), +2% from Q1 2026.
How has Journey Medical's Qbrexza revenue changed?
Over the last 7 quarters it ranged from $5.0M (Q1 2026) to $7.4M (Q3 2025).